The percentages of Bregs among total CD19+ B lymphocytes were significantly decreased in ND AML patients compared to healthy controls (0.61% ± 0.44% vs. 3.67% ± 1.04%, P < 0.001) (Figures 1(a) and 1(b)). Here, CD19 is linked to acute myeloid leukemia.